Spruce’s successful FDA talks plant seeds for Q4 filing of ultra-rare disease drug

Spruce Biosciences has taken another step toward filing for FDA approval of its ultra-rare disease drug candidate, ticking off some of the manufacturing tasks needed to submit the long-awaited application.